

PRESS RELEASE

Camurus to present at Jefferies London Healthcare Conference

Lund, Sweden — 11 November 2024 — Camurus (NASDAQ STO: CAMX) announces that Fredrik Tiberg, President and CEO, is presenting at the Jefferies Healthcare Conference in London on 20 November at 1.30 pm local time (GMT), giving an update on the company's recent development and progress.

A webcast of the presentation can be accessed via:

<https://wsw.com/webcast/jeff315/camx.st/2236248>

For more information

Fredrik Joabsson, Chief Business Development Officer

Tel. +46 (0)70 776 17 37

ir@camurus.com

About Camurus

Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

This information was submitted for publication at 10:00 am CET on 11 November 2024.